|
Publications
- N. Muirhead, BF Feagan, J. Mahon, RZ Lewanczuk, NW Rodger, F. Botteri, P. Oddou-Stock, E. Pecher, R. Cheung: The Effects of Valsartan and Captopril on Reducing Microalbuminuria in Patients with Type 2 Diabetes Mellitus: A placebo-controlled trial. In: Current Therapeutic Research Clinical and Experimental. Dec 1999; 60 (12): 650-660
- R. Cheung, R. Lewanczuk, W. Rodger, Huff, P. Oddou-Stock, F. Botteri, E. Pecher, N. Muirhead: The Effect of Valsartan and Captopril on Lipid Parameters in Patients with Type II Diabetes Mellitus and Nephropathy. In: International Journal of Clinical Practice. Dec. 1999; 53(8): 584-592.
-Muller-Lissner SA, Fumagalli I, Bardhan KD, Pace F, Pecher E, Nault B, Ruegg P.: Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther. 2001 Oct;15(10):1655-66.
- Tougas, G., Snape, W. J., Otten, M. H., Earnest, D. L., Langaker, K. -E., Pruitt, R. E., Pecher, E., Nault, B. & Rojavin, M. A.: Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Alimentary Pharmacology & Therapeutics 16 (10), 1701-1708. (2002)
- Carola Saloranta, Christiane Guitard, Eckhard Pecher, Pedro de Pablos-Velasco, Kaj Lahti, Patrick Brunel, and Leif Groop. Nateglinide Improves Early Insulin Secretion and Controls Postprandial Glucose Excursions in a Prediabetic Population. Diabetes Care 25: 2141-2146 (2002).
- S. Haffner, R. Holman, R. Califf, J. McMurray, E. Pecher, R. Pratley on behalf of the Navigator Trial Steering Committee. Targeting post-prandial hyperglycemia to prevent type 2 diabetes: Rationale and design of the NAVIGATOR trial (Abstract). 38th annual meeting of the European Association for the Study of Diabetes (2002).
- Quigley EM, Wald A, Fidelholtz J, Biovin M, Pecher E, Earnest D: Safety and tolerability of tegaserod in patients with chronic constipation: Pooled data from two phase III studies. Clin Gastroenterol Hepatol. 2006 May; 4(5):605-13
(Other abstracts not listed)
|